Planning a programme of pre-authorisation clinical trials of medicines for the treatment of chronic hepatitis C

In 2016 the WHO Assembly defined a global strategy to combat viral hepatitis viruses, which seeks to eliminate these infections by 2030. The most important goals of this programme, adopted by 194 countries, are to reduce the incidence of viral hepatitis by 90 % and mortality rates – by 65 % as compared to the levels observed in 2016. Therefore, there is an obvious need for development of medicines for the treatment of chronic hepatitis C. The aim of the present paper was to determine basic approaches to planning pre-authorisation clinical trials for the main groups of medicines for the treatment of chronic hepatitis C. The paper summarises the current trends in the treatment of chronic hepatitis C; it lists medicines with direct antiviral effect that are currently registered in the Russian Federation, as well as interferon-free and interferon-containing regimens for the treatment of this disease. The authors examined the current requirements in force in the Russian Federation, namely: the Federal Law No. 61-FZ «On circulation of medicines» dated April 12, 2010, the Guideline on Evaluation of Medicinal Products, the Clinical Recommendations for Diagnosis and Treatment of Adult Patients with Hepatitis C, as well as recommendations of the European Medicines Agency and the Food and Drug Administration in order to analyse the planning of programmes of pre-authorisation clinical trials of interferon alfa products and direct antivirals. 

1. Kukes VG, ed. Clinical pharmacology. Moscow: GEOTAR-Media; 2015 (In Russ.)

2. Yushchuk ND, Klimova EA. Treatment of chronic hepatitis C in Russia: modern possibilities and the immediate prospects. Infektsionnye bolezni: novosti, mneniya, obuchenie = Infectious Diseases: News, Opinions, Training. 2017;(2):86‒95 (In Russ.).

3. Ivashkin VT, Yushchuk ND, eds. Recommendations for the diagnosis and treatment of adult patients with hepatitis B and C. In: Clinical recommendations. Moscow: GEOTAR-Media; 2015 (In Russ.)

4. Gubenko AI, Eremenko NN. Chronic hepatitis С: common and new approaches to protease inhibitors including treatment. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya = Тhе Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2013;(4):22‒5 (In Russ.)

5. Moiseev SV, Abdurakhmanov DT. Personalised therapy of chronic hepatitis C. Klinicheskaya gepatologyia = Clinical Hepatology. 2012;(2):44‒8 (In Russ.)

6. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie АM, Reddy KR, Bzowej NK, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405‒16. https://doi.org/10.1056/NEJMoa1012912

7. Poordad F, McCone J, Bacon B, Bruno S, Manns M, Sulkowski M, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195‒206. https://doi.org/10.1056/NEJMoa1010494

8. Blokhina NP, Malyshev NA, Nurmukhametova EA. Hepatitis C treatment – the present state and future prospects. Tuberkulez i social’no-znachimye zabolevaniya = Tuberculosis and Socially Significant Diseases. 2013;(1):73‒8 (In Russ.)

9. Shipulin VP, Kuz’minets AA. Features of treatment of patients infected with hepatitis C virus genotypes 1 and 4 by direct-acting antiviral drugs. Gastroenterologiya = Gastroenterology. 2016;(3):51‒7 (In Russ.) https://doi.org/10.22141/2308-2097.3.61.2016.79160

10. Mitsura VM, Krasavtsev EL, Zhavoronok SV, Voropaev EV, Osipkina OV, Soldatenko OV, et al. Antiviral treatment of chronic hepatitis С: available results and future prospects. Problemy zdorov’ya i ekologii = Health and Environmental Issues. 2017;(1):31‒5 (In Russ.)